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Abstract
There is a growing expectation of physicians to treat acute pain more aggres-
sively in the emergency department (ED). This has contributed to an increase in 
opiate prescribing practices that has resulted in a crisis of medication abuse and 
misuse. The resultant backlash against physicians has created a void within the 
realm of acute pain management, as physicians search for a means to treat their 
patients in a way that is both empathetic and responsible. In an effort to combat this 
growing epidemic, alternative means of pain control are being explored. Patient-
controlled analgesia devices (PCADs) have been used extensively in multiple fields 
of medicine and have demonstrated significant clinical utility for treating pain 
postoperatively; however there is a dearth of evidence to support their use within 
the acute care setting. Due to this lack of evidence, PCADs have not been widely 
implemented in the ED. Recent studies have shown that the use of PCADs may 
improve objective pain scores and increase both patient and nurse satisfaction while 
reducing the likelihood of developing chronic pain. The economic feasibility of 
this undertaking remains unclear; however there is strong evidence for the clinical 
utility of this modality to treat acute pain in this population.
Keywords: pain, emergency department, treatment, patient-controlled analgesia, 
patients-controlled analgesia devices, oligoanalgesia, patient satisfaction, 
patient autonomy
1. Introduction
Although there are discrepancies in prevalence among different emergency 
departments (ED), pain is the primary presenting complaint in 45–75% of all ED 
visits [1]. To put this in perspective, it is important to note just how significantly 
the landscape of the ED has changed over the last 20 years. Between 1996 and 2015 
there was a 46% increase in the utilization of emergency services in the United 
States with 136 million people seeking emergency care in 2015. This equates to over 
100 million patients presenting to the ED in acute pain [2]. As emergency room 
visits continue to grow every year, so does the need to find effective treatments for 
patients experiencing such episodes. Currently, the standard of care in most EDs 
includes the use of intravenous (IV) opiates which are titrated subjectively accord-
ing to patient complaints; however this is often significantly impacted by outside 
forces including nursing availability and patient census. Unfortunately, in many 
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cases a baseline pain score is not adequately established which leads to substantial 
variations in treatment, with the end result being that patients experience increased 
pain and less satisfaction with their care. Inadequate pain relief, otherwise known as 
oligoanalgesia, can lead to a myriad of psychological and physiologic consequences 
which can extend far beyond the initial injury. Thus, early intervention to treat 
acute pain is integral to effective patient care.
Current guidelines established by the American Academy of Emergency 
Medicine Physicians suggest that “parenteral opioids should be titrated regardless 
of the initial dosing regimen (i.e., weight-based, fixed, or nurse-initiated) at 20–30 
minutes intervals until pain is relieved to acceptable levels with frequent re-
assessment and evaluation for development of opioid-related adverse effects.” [3] 
Although this schedule may appear ideal, re-dosing of medication at this frequency 
requires significant time from nursing staff and physicians and may prove difficult 
given the demanding pace characteristic of most emergency departments. This 
is problematic from both a practice and administrative standpoint, as increasing 
patient volumes are taxing our already overburdened EDs. From a clinical perspec-
tive this translates into substantial delays in achieving adequate analgesia and pro-
longed wait times between doses for patients in acute pain. In light of these issues, it 
is clear that physicians and ED staff must reconsider their current approach to pain 
management and explore novel methods to improve treatment efficiency without 
sacrificing quality.
Within the last 20 years, there have been increasing demands placed on ED 
physicians and staff to aggressively treat acute pain in an effort to improve patient 
satisfaction, improve outcomes and meet core measures. Consequently, the 
“Emergency Department Measure Set” was developed by the Centers for Medicare 
and Medicaid Services (CMS) and has been adopted by The Joint Commission’s 
ORYX program in order to maintain alignment with CMS reporting requirements 
[4]. These, and many additional factors, have contributed to an increase in opiate 
prescriptions which has resulted in a crisis of medication abuse and misuse which 
continues to plague EDs all over the country. The resultant backlash against both 
physicians and pharmaceutical companies has created a void within the realm of 
acute pain management, as physicians search for a means to treat their patients in 
a way that is both empathetic and responsible. Patient-controlled analgesia, which 
has long been accepted as an appropriate form of pain management in post-surgical 
care, has shown promising results in its application in the acute care setting and 
may prove to be an invaluable tool which may be used for effective multimodal pain 
control.
Patient-controlled analgesia offers multiple benefits to patients in acute pain. 
The devices themselves are relatively easy to set up, they reduce delays and treat-
ment variability, and provide patients with increased control of their analgesic 
needs. Delivery of medication via this method also avoids the peaks and troughs 
in blood levels associated with irregular bolus dosing and allows for a steady-state 
concentration within the plasma [5]. By controlling both the frequency and quan-
tity of medication being delivered, patients are able to achieve improved levels of 
analgesia while minimizing the risk of adverse events. Dynamic systems such as this 
allow for increased patient autonomy and improved personalization of care without 
the requirement of additional supervision by staff.
2. The risks of undertreating pain
Although many patients achieve full resolution of pain after an acute episode, 
it has been demonstrated that pain may persist in up to 21% of patients being 
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discharged from the ED [6, 7]. The precise mechanism for the transition from acute 
to chronic pain is poorly understood, however, the practical implications of this 
issue are becoming increasingly apparent as the number of patients experiencing 
chronic pain has reached epic proportions. Patients experiencing traumatic pain 
and acute abdominal pain are especially at risk for developing chronic pain and 
these populations make up a significant amount of ED admissions. In addition to 
the mechanism of injury there is also a myriad of different symptoms which can 
predispose individuals to developing persistent pain including age, gender, genetics, 
pain trajectory and pre-existing anxiety/depression [7]. Although many of these 
cannot be adequately controlled for in an acute setting, pain trajectory is one of the 
main factors that can be actively affected by emergency physicians and PCADs have 
shown increasing effectiveness in this regard. A recent study conducted by Rockett 
et al., demonstrated that utilization of PCADs in the emergency room significantly 
decreased the number of patients experiencing persistent pain from non-traumatic 
abdominal injuries, 6 months post-injury. “The study findings suggest that it may 
be possible to reduce persistent pain (at least in patients with abdominal pain) 
by delivering better acute pain management” [7]. Consequently, it appears that 
increased utilization of patient-controlled analgesia may be a viable alternative to 
our current practice model which can provide increased comfort to both provider 
and patient while diminishing the number of patients developing persistent pain.
3. Background on patient-controlled analgesia devices
Patient-controlled analgesia devices were first developed in the 1960s in an 
effort to allow patients to control their pain without the requirement of frequent 
nursing intervention [8]. The device itself has gone through significant changes 
with regards to technology, however its basic purpose remains the same. PCADs 
generally consist of a volumetric pump which contains opiate medications that may 
be delivered intravenously once a patient presses the button controlling outflow. 
The device often contains additional control measures including anti-siphon 
and anti-reflux valves which allow for precision in the quantity of dosing while 
minimizing the risk of inadvertent medication administration [9]. Physicians may 
control several variables including the loading dose, demand/bolus dose, lock-out 
interval and quantity required for continuous infusions [5]. In the initial stage of 
treatment a bolus or loading dose is commonly administered to establish a baseline 
degree of analgesia. Afterwards there is a lock-out period during which the pump 
does not release any additional medication. Patients may continue to press the 
release trigger during this period of time but no additional doses are released. A 
number of demand requests are logged by the device and can help guide physi-
cians when attempting to determine an optimal dosing strategy for each individual 
patient.
Dosing parameters are generally set by the physician and should reflect the level 
of pain being experienced by the patient as well as the patient’s expected length 
of stay in the ED, body habitus, and previous use and tolerance to analgesics. An 
optimal dosing strategy is one that would allow for maximum analgesia while 
minimizing potential side effects. With traditional dosing methods this is difficult 
to achieve. To remedy this, several protocols have been developed for use in patient-
controlled analgesia which have been demonstrated to be effective in most patients. 
For instance, a common protocol used in both the US and UK includes a loading 
dose of 1 mg of morphine followed by a 5 minutes lockout period and subsequent 
bolus dosing of 1 mg [10]. Lock-out times are an important safety concern among 
physicians for obvious reasons, however studies show that increments between 5 
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and 10 minutes are generally considered safe regardless of the type of medication 
being used [5]. These parameters can be altered in real time in response to patient 
feedback. This allows for more dynamic analgesic control which has clear benefits 
for patients presenting to the ED with acute pain.
It is important to note that there are distinct differences between machine 
programming parameters for postoperative patients versus those in an emergency 
setting. A prime example of this is the use of background/continuous infusions. 
Utilization of this setting allows for increased baseline plasma levels of medication 
and may improve pain control in certain populations [5]. Although the literature 
supports this type of treatment in post-operative patients, it may not be ideal for 
the ED as it requires close maintenance by nursing staff. Additionally, research 
shows that it does not improve pain control significantly in this patient population 
and may actually lead to increased incidence of adverse events including respira-
tory depression and sedation [5]. In another study which specifically examined the 
use of background infusions in the ED it was also found that manipulation of this 
setting led to an increased rate of pump programming errors. Although the patients 
involved in this study did not sustain any long-term side effects, there was an 
increase in the rate of sedation which further supports that this setting is of limited 
use in the ED [11].
4. General principles in acute pain management
The use of opiate medication in acute pain management has been a staple in 
most busy emergency departments. They work via blockade of μ-opioid receptor-
channels which inhibit the transmission of pain in the central nervous system. In 
general, pure μ agonists have a high degree of variation in terms of dose-response 
relationships among individuals and require close monitoring by medical staff [1]. 
Side effects of medications which target μ-opioid receptors include respiratory 
depression, sedation, nausea, vomiting and pruritus. The frequency of adverse 
events associated with opiate administration in an acute care setting is difficult 
to predict and often, a trial of medication is necessary before sensitivities can be 
established. The disparities among these patients in regard to appropriate analgesic 
control is multifactorial and includes differences in opiate tolerance, pain sever-
ity, previous opiate use, body habitus, height and weight, dosing quantity and 
the frequency of administration. Many of these factors are difficult to control in 
a fast-paced environment such as the emergency room. However, utilization of 
patient-controlled analgesia may help offset these issues by allowing patients to take 
a more active role in the management of their pain.
Common opiates used in this setting include morphine, hydromorphone, and 
fentanyl. They are widely available and physicians are familiar with their general 
dose-response relationships and safety profiles. Although studies have shown that 
usage of specific opiates does not necessarily correlate with significant differences 
in pain scores among patients using PCADs, this does not obfuscate the need for 
appropriate medication selection [5]. Thus, it is important to take an individualized 
approach when selecting which medication a patient will receive.
4.1 Opiate selection
4.1.1 Morphine
Morphine is the most commonly used opiate in EDs which is likely due to its 
intermediate half-life, moderate strength and familiarity among hospital staff. 
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The average half-life of morphine is 1.5–2 hours with peak intensity usually being 
established in approximately 90 minutes [12, 13]. This makes it an effective medi-
cation for pain control as its effects wear off in a reasonable amount of time and 
it is generally well tolerated. Analgesic dosing is usually 0.5–3 mg per bolus, with 
a lockout period of 5–20 minutes [5]. Due to morphine’s longer onset of action it 
could accumulate in the plasma and could result in analgesic stacking if the lock-
out times are not calibrated appropriately. Although this could theoretically lead 
to a significant increase in adverse events; it is very rarely seen clinically when 
administering conventional PCAD level dosages [5]. Additionally, it is important to 
recall that morphine has a higher degree of histamine release than other opiates in 
its class. This may preclude it from use in patients that have a history or pruritus or 
flushing after morphine use. This is, however, only a relative contraindication and 
may not manifest as readily due to the decreased quantity of medication adminis-
tered in each dose.
4.1.2 Hydromorphone (Dilaudid)
Hydromorphone is a medication that is both incredibly effective but also 
increasingly maligned by emergency physicians. It has gained notoriety due to its 
strength and efficacy in acute pain management and it is widely available in most 
EDs. Unfortunately, these attributes have also made it a popular drug of abuse 
among pain seekers and physicians remain wary of regular use. It is seven times 
more potent than morphine and is broken down into a biologically inactive metabo-
lite which makes it an excellent candidate for patients requiring repeat dosing of 
opioid medications. It also has an improved side effect profile, including diminished 
histamine release, which results in less pruritus. The time to peak analgesic effect 
for hydromorphone is approximately 20 minutes and its dose equivalent when 
compared to morphine ranges from 4–8 to 1 which can make precise conversions 
difficult [13]. Although hydromorphone is considerably more potent than mor-
phine studies have demonstrated that PCADs utilizing hydromorphone are equally 
effective in comparison to morphine PCADs when dosing toward equianalgesia 
[13]. Typical dosing for hydromorphone is 0.1–0.5 mg followed by a 5–15 minutes 
lockout interval [5]. A recent study comparing the efficacy of morphine and 
hydromorphone concluded that the side effect profile is similar between morphine 
and hydromorphone in terms of opiate-related side effects [13]. Additionally, pain 
control and patient satisfaction were also equivalent. Thus it appears that priori-
tization of one medication over another should likely be guided by patient history 
as each drug has a unique side effect profile which may preclude it from usage in 
certain groups. Unfortunately, due to the past history of hydromorphone misuse in 
the ED it will likely remain as a secondary agent.
4.1.3 Fentanyl
Fentanyl has long been a preferred drug in ED for patients in severe acute pain as 
it reaches peak concentrations quickly within 1–2 minutes and has a short half-life 
(6 minutes) [14]. This makes it an excellent candidate for patients that require 
timely analgesia without a lengthy period of sedation. Fentanyl is well suited for 
use with PCADs as repetitive dosing at appropriate lockout intervals has not been 
shown to lead to excessive accumulation in the plasma and thus, does not result in 
analgesic stacking [15]. Intravenous dosing of Fentanyl usually consists of 15–50 μg 
followed by a 3–10 minutes lockout period. Although intravenous administra-
tion of this medication remains popular, novel delivery methods have recently 
been explored which show promising results. Transdermal Fentanyl is becoming 
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increasingly popular in the realm of patient-controlled analgesia, as it has been 
demonstrated to have increased ease of use (i.e. improved confidence/comfort with 
the device, dosing, and knowledge/understanding) and less technical issues associ-
ated with autonomous administration. Although the transdermal route of delivery 
has been notorious for inconsistencies in medication delivery/absorption it appears 
as though transdermal Fentanyl produces results in terms of pain control and 
patient satisfaction which are on par with morphine [16]. Additionally, studies have 
also demonstrated that it has an improved side effect profile and has less frequent 
adverse events associated with its use, including hypotension, hypoventilation, nau-
sea, vomiting, pruritus and tachycardia [17]. As such, it may be a viable alternative 
for patients who have sensitivities to more traditional medications like morphine.
4.1.4 Meperidine (Demerol)
Meperidine is another common opiate that has been studied as an alternative 
to morphine for use in patient-controlled analgesia, however it has limited utility 
in the ED. Meperidine has numerous disadvantages, including a short duration of 
action, a very poor analgesic effect at common doses (25–50 mg), abuse potential, 
and concerning drug interactions. Meperidine has serotonergic and noradrenergic 
properties and has the potential to induce serotonin syndrome in patients taking 
selective serotonin reuptake inhibitors and monoamine oxidase inhibitors [18].
A head-to-head comparison was recently done which evaluated meperidine 
versus morphine use in patients utilizing patient-controlled analgesia who were 
chronic opiate users presenting to the emergency room in acute pain. Levels of 
analgesia among the two groups were similar; however, patients using meperidine 
had a greater likelihood of experiencing withdrawal symptoms afterwards which 
was reflected in increased COWS scores [19]. Additionally, meperidine has a less 
favorable side effect profile when compared to morphine as it is broken down into 
the biologically active metabolite, normeperidine, which is a neurotoxin that can 
accumulate in the plasma and increases the risk of seizures, delirium, tremors, 
myoclonus and restlessness [5, 20]. It is important that patients be closely moni-
tored when receiving this medication. Increased need for staff supervision would 
likely negate many of the benefits which PCADs provide in an acute care setting. 
For these reasons, meperidine is a poor choice for acute pain and should be used 
with caution in the ED [5, 21].
4.2 Additional modes of administration
There are numerous alternative modes of medication administration in 
patient-controlled analgesia including oral/sublingual, transdermal, intranasal, 
inhalational, and epidural preparations [22]. Intravenous delivery has remained 
the most popular route of administration, however, studies have shown promising 
results for several of these alternatives. Oral/sublingual medication, in particular, 
may have increased utility in the ED as it has the added benefit of being less invasive 
than standard IV therapy and may be preferable for some patients who are not 
candidates for inpatient admission. A meta-analysis of 13 studies demonstrated 
that sublingual medication administration had less side effects and a statistically 
significant improvement in global assessment scores (defined as “good” or “excel-
lent”) as well as trends which indicated improvements in VAS when compared to 
both morphine and transdermal Fentanyl [23].
In light of this information, a novel, non-invasive delivery system has 
recently been developed for the newly FDA approved medication, sufentanil. 
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This sublingual delivery device has been specifically designed for use in patient-
controlled analgesia and has demonstrated excellent titratability and a rapid 
onset of action which makes it attractive for use in the ED [24]. Phase 3 trials have 
demonstrated that sublingual Sufentanil has greater efficacy for the treatment 
of pain than IV medications and has less incidence of oxygen desaturation in the 
populations being studied [24]. Additionally, a recently conducted prospective, 
randomized double-blind study has shown that patients receiving sublingual 
Sufentanil have a higher summed pain intensity difference and improved global 
assessment scores in comparison to placebo [25]. Although this initial data appears 
promising, further studies must be done in an acute care setting before this device 
can be recommended specifically for use in the emergency department.
In additional to oral preparations there may be increased utility for medication 
delivery via the intranasal or inhalation route as these may also decrease the need 
for IV insertion and reduce overall cost. Unfortunately there are still significant 
barriers which must be overcome before these devices become commonplace. 
Inhalational medication, in particular, offers clear benefits as it is non-invasive, 
has a rapid onset of action and improved bioavailability [8, 26]. It has not been 
embraced in its current form; however, due to technical issues with regard to medi-
cation delivery, and improper patient compliance. Intranasal administration has 
been plagued by similar issues; however this may change in the future as technology 
improves and devices are able to deliver medication more effectively.
For the sake of completeness, epidural preparations should be briefly discussed 
as they are widely utilized in the perioperative and postoperative setting and have 
been shown to be more effective at controlling pain than intravenous administration 
[8, 27]. Epidural delivery of medication allows for targeted placement of opiates 
adjacent to the spinal afferent pain receptors which may diminish the systemic 
effects seen with oral and intravenous administration. This would initially appear 
promising for ED physicians as they are continually searching for ways to reduce the 
quantities of opiates being prescribed to their patients. Unfortunately this requires 
placement of an epidural catheter by a trained physician (often an anesthesiologist) 
which would not be feasible within the scope of the emergency department. Thus, 
the feasibility of its implementation in this setting is limited.
5. Special populations
5.1 Children
PCAD usage is considered safe for autonomous use in children over 6 who are 
experiencing acute pain [5]. Studies have demonstrated that PCAD use in this 
population results in decreased total opiate use, improved analgesia and decreased 
adverse effects, making it an ideal alternative to standard therapy [28]. One of the 
main determinants which govern its effective use in this population is the ability 
of the child to understand how and why the device is being used. The child must 
be able to understand basic principles regarding their pain as they will be required 
to follow instructions on how to self-administer medication. Studies have demon-
strated that PCAD use in children under 4 is ineffective due to the aforementioned 
issues; however, children between 4 and 6 may use the device with the caveat 
that they maintain close nursing oversight. The need for additional monitoring 
is important for patient safety but this may not be feasible in a busy ED. Parental 
controlled patient analgesia has been offered as an alternative to this but in order to 
be effective it requires one-on-one education from nursing staff which also takes 
From Conventional to Innovative Approaches for Pain Treatment
8
time and cooperation from a third party which may be cumbersome to facilitate. 
Parental controlled analgesia also has the added detractor that it removes the 
inherent benefits of patient autonomy which PCADs provide. Thus, it is unlikely to 
demonstrate a significant benefit over IV morphine for the purposes of acute pain 
management.
Morphine remains the most commonly used medication for patient-controlled 
analgesia in the pediatric population [28]. Typical dosing consists of a bolus of 
10–20 μg/kg and a lockout period of 7–15 minutes [5]. As with all pain medications 
there are issues that may arise with prolonged administration of Morphine, which 
is especially concerning in the pediatric population. Cycling narcotics, especially 
in children who will be admitted, can help combat some of the sensitivities that 
are seen in relation to morphine utilization. Switching to medications such as 
hydromorphone can help decrease side effects like pruritus which may be both 
uncomfortable and alarming to many children. Hydromorphone, morphine and 
fentanyl are all considered safe for use in the pediatric population and they may be 
used interchangeably depending on response to treatment. A recent study found 
that hydromorphone to morphine switches for patient using PCADS was far more 
common (88.5% versus 11.5%) than vice versa. The most common reason for 
switching morphine to hydromorphone in this cohort was due to pruritus and inad-
equate pain control. Hydromorphone to morphine switches were more commonly 
due to nausea. Thus, physicians should monitor this population closely and change 
medications as necessary should any adverse events arise.
5.2 Geriatrics
Acute pain relief in the elderly can be challenging. Elderly patients presenting 
to the ED frequently have multiple comorbidities and physiologic issues which 
can affect the way in which analgesics are metabolized. Acute pain control in the 
geriatric population is an important topic to address because it is integral to their 
recovery. Studies have shown that unrelieved episodes of acute pain can result in 
decreased pulmonary function, sympathetic hyperactivity (including tachycardia 
and hypertension) and central neural sensitization which can lead to the develop-
ment of chronic pain [29]. PCAD use is well suited for this population as it allows 
for individualized dosing, decreased fluctuations in opiate plasma concentra-
tion and improved pain control [30]. A recent study by Egbert which included 
83 high-risk elderly men, demonstrated that PCAD use had improved analgesia 
without a concomitant increase in adverse events such as sedation. Additionally, the 
patient-controlled analgesia group reported that the PCAD was easier to use than 
traditional therapy [30].
Drug choice is important in the elderly as the pharmacokinetics and pharma-
codynamic profile of opiate medications changes throughout the aging process. As 
we age there is an increase in body fat and decrease in total body water which alters 
drug metabolism. Therefore, fat soluble drugs such as fentanyl and meperidine 
have a higher volume of distribution and a longer duration of action which make 
them less attractive for use in this population [29]. Morphine is the most widely 
used medication for PCADs in the elderly and studies have demonstrated that the 
optimal loading dose is 1.0–1.5 mg/dose which should be followed by similar bolus 
dosing after a 5–7 minutes lockout period. It is important to note that water soluble 
drugs such as morphine have a higher plasma concentration in elderly patients due 
to their redsuced volume of distribution as well as increased levels of free active 
drug due to reduced albumin synthesis. As such, continuous infusions are contra-
indicated in this population as there is an increased frequency of adverse events, 
namely respiratory depression and hypotension [29].
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5.3 Chronic opiate users
Pain control is notoriously difficult in patients who chronically use opiates 
and they often remain undertreated [31]. Although PCAD use in this population 
remains controversial, it may prove effective when used selectively [32]. Unlike 
patients who are opiate naive, bolus dosing in chronic opioid users may necessitate 
periodic re-adjustments, as larger doses are usually required with shorter lockout 
periods [31]. By providing these patients with a more uniform dose of medication 
ED physicians can avoid sedation while also decreasing the propensity for anxiety 
and cravings that occur frequently with IV therapy. Some physicians may also 
be worried about the potential for increased medication administration, should 
patients attempt to tamper with the device. This is usually not possible with stan-
dard pumps though, as they contain safety precautions and redundancies within 
the structure of the device which limit the potential for abuse. It should be noted 
however, that the “wrist-watch” type of PCAD contains a reservoir which is less 
secure than standard devices and it has a fixed lockout schedule which makes it less 
attractive for use in this population [31].
In regards to medication selection, morphine is a commonly used medication 
which remains effective, albeit at higher concentrations, even in patients that 
have developed a tolerance. Studies which directly evaluated morphine use in ED 
patients receiving patient-controlled analgesia are limited but, as noted previously, 
there is a clear benefit to using morphine over other alternatives for numerous rea-
sons [19]. Hydromorphone is another alternative that might initially seem appeal-
ing, however there is a push to limit its use in the ED, especially for chronic opioid 
users, so it is unlikely that it would gain widespread acceptance. Alternatively, one 
medication which has shown good efficacy for the treatment of acute pain is oral 
transmucosal fentanyl. Studies show that this medication is effective in chronic 
opioid users with breakthrough pain and may be a viable alternative for patients 
where morphine is initially ineffective or patient sensitivities preclude its use [10].
6. Benefits of patient-controlled analgesia use in the ED
6.1 Opiate utilization
One of the more divisive topics relating to PCAD implementation in the emer-
gency room relates to risk of abuse and reliance on opiates by patients provided with 
opiate analgesia. Initial systematic reviews regarding this subject demonstrated 
that patients using PCADs in the postoperative setting required less opiates than 
those undergoing standard therapy [8]. Unfortunately this does not appear to be the 
case for patients presenting to the ED. Evaluation of the most current randomized 
controlled trials for PCAD use in this population have demonstrated that patients 
receiving this therapy utilize a greater quantity of opiates than those receiving 
intravenous morphine [11, 33]. A recent study done by Bijur which included 636 
patients presenting to the ED in acute pain, demonstrated that patients utilizing 
a PCAD required significantly more morphine (12.0 mg ± 4.3 versus 6.1 mg ± 2.9; 
95% CI: 5.9 [5.2–6.4]) than those in the standard therapy group [11]. This data may 
seem worrisome at first but, as previously discussed, patients presenting to the ED 
with acute pain are notoriously undertreated. As such, the increased utilization of 
opiates in this population may reflect that patients need higher levels of analgesia 
than provided by standard measures of nurse administered analgesia.
In an effort to mollify this effect, recent studies have evaluated the efficacy 
of adding non-opiate medications to traditional PCAD formulations, with the 
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expectation there would be a level of opiate sparing and analgesic synergy. One of 
the most commonly studied of these additives is the NMDA inhibitor, Ketamine. 
This medication is of particular interest to emergency physicians as it is widely 
available and used frequently in both the pediatric and adult populations in pro-
cedures such as rapid-sequence intubation and procedural sedation. It has a favor-
able pharmacokinetic profile in terms of pain management as it has both intrinsic 
analgesic properties and opiate sparing effects via antagonism of NMDA receptors 
[5, 34]. Unfortunately, research on this subject has been mixed as some studies 
have shown that it may not provide a significant reduction in pain scores and has an 
increased incidence of deleterious side effects [5, 35, 36]. Clonidine has also been 
used as an additive in PCADs and initially showed some benefits in regard to nausea 
reduction in certain post-operative patients but this has not been reliably repro-
duced in subsequent studies [5, 34, 37].
One medication which has shown promise for use with PCADs is dexmedeto-
midine. This medication is a “highly selective α2-adrenoreceptor agonist, with 
analgesic, anxiolytic, and sedative properties, but without effects on respiratory 
function.” [5, 38] In a recent study it was shown that adding dexmedetomidine to 
PCADs with morphine resulted in improved analgesia, decreased nausea and sig-
nificant morphine sparing, without significantly impacting patients hemodynamic 
status [5, 39]. Thus, it would appear that this medication would be particularly well-
suited for use in the ED. Optimal dosing of this medication has not been definitively 
established, however the concentration used in this study consisted of 5 μg/mL 
with the PCAD being programmed to deliver 1 mL per demand bolus followed 
by a 5-minute lockout period. Formulations such as this are determined by the 
pharmacokinetic properties of the medication being studied and mixtures of these 
medications generally require additional assistance by pharmacy staff. This would 
likely add additional hard costs with regard to medication preparation but this may 
be a viable option for patients with a labile hemodynamic status (such as the elderly, 
septic or traumatically injured) where the analgesic benefits of increased dosing 
may be tempered by the fear of respiratory depression or hypotension. Additionally, 
these additives would offer a clear benefit for chronic opiate users where opiate 
sparing may be of increased importance.
6.2 Pain reduction
The perception of pain is highly subjective and varies greatly among individuals 
and makes it difficult to measure in precise terms. That being said, multiple formal 
measures have been created to objectively measure reductions in pain, namely the 
Visual Analogue Scale score (VAS score) and Numeric Rating Scales (NRS). These 
tools are of primary importance to both patients and physicians in objectifying 
levels of pain. Studies show that improvement in pain scores are directly correlated 
with patient satisfaction which can significantly influence the clinical course of 
patients experiencing an episode of acute pain [40]. Although it is well established 
that PCADs reduce pain scores in the post-operative setting there has been some 
controversy as to whether this would hold true for ED patients, as they often do not 
have as much time to convalesce from injuries. In reviewing the literature it appears 
that eight randomized controlled trials have been done which specifically examined 
the effect that patient-controlled analgesia had on pain scores in patients present-
ing to the ED. Five out of the eight studies in question have shown statistically 
significant results which favor PCAD use over conventional intravenous therapy. 
Two of the remaining studies demonstrated a downward trend which favored 
PCADs (although this did not reach the threshold for statistical significance) and 
only one study showed no difference [9, 11, 33, 41–46]. Unfortunately there is 
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significant heterogeneity among these studies and due to the wide range of present-
ing complaints there are many confounding factors which must be accounted for. 
That being said, the initial data appears to support the use of PCADs over standard 
therapy for patients presenting to the ED with acute pain.
6.3 Patient autonomy and patient satisfaction
Patient satisfaction is becoming ever more important in clinical medicine. It 
is imperative that physicians maximize their ability to take care of patients in an 
empathetic manner which utilizes principles of patient autonomy and shared deci-
sion making. Studies have demonstrated that PCADs are preferred by many patients 
in comparison with both IV and IM preparations and patient satisfaction with 
this type of treatment is generally high [5, 9, 11, 33, 41–46]. In a recent systematic 
review of 21 trials which included 1260 postoperative patients, it was shown that 
patients had increased satisfaction with PCAD use in all of the studies that were 
included in the cohort [8]. Additionally, a meta-analysis done on the same group 
showed that patients preferred PCADs significantly more than standard therapy 
[8]. Studies which have been conducted that have evaluated patient satisfaction for 
patients presenting to the emergency room have also shown similar results, with 
the overwhelming majority of studies showing a clear preference for PCADs [9, 11, 
33, 41–46]. This is likely due to several factors including faster time to analgesia, 
decreased need of nursing assistance and an increased sense of autonomy and 
control over one’s pain [44].
In addition to patient satisfaction it is important to remember that proper 
implementation of this technology requires cooperation across multiple disciplines. 
As such, the support of physician extenders, nurses, and hospital pharmacists is 
integral to patient care and should not be overlooked. Relatively few studies have 
addressed this issue directly but current evidence shows that PCADs are generally 
well received by nursing staff. One study in particular demonstrated that patient-
controlled analgesia regiments were rated as “good to excellent” more frequently 
than those utilizing traditional intravenous therapy (69% versus 54%) and the 
majority of nursing staff would use them again in the future (77%) [41].
7. Drawbacks of patient-controlled analgesia use
The majority of studies which have examined PCAD use in the emergency set-
ting have found that there were similar rates of side effects such as nausea, vomit-
ing, pruritus and drowsiness when compared to those receiving standard therapy 
[9, 11, 33, 41–46]. However, two studies showed PCADs to have a slightly increased 
risk of adverse events, including hypotension and hypoventilation, although 
neither group experienced any long-term sequelae in connection with these events. 
Additionally, these effects were transient and did not require the use of reversal 
with naloxone [9, 11]. When evaluating the literature it appears that the preponder-
ance of adverse events associated with PCAD use have been due to factors which are 
inherent to all sustained opioid use and would likely be minimized with appropri-
ate monitoring by staff. It is important to note that certain subgroups of patients 
may be prone to respiratory depression with patient-controlled analgesia. Studies 
have shown that elderly patients, patients with obstructive sleep apnea, and those 
using concurrent analgesics are at particular risk, and are vulnerable to the sedative 
effects which occur with repeated dosing [22].
Although it appears that PCADs are safe in this patient population, there are 
unique characteristics associated with this technology which require special attention 
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and education for both patients and staff. Programming errors can occur, especially 
when staff are unfamiliar with the equipment which can lead to over-sedation and 
respiratory depression. In a large randomized study conducted in the ED by Bijur 
et al. there were a similar number of adverse events among patients assigned to the 
PCAD group versus those receiving standard IV therapy. However, the PCAD group 
had 11 pump programming errors, 10 of which were due to nursing staff uninten-
tionally giving patients background infusions. None of the patients in question were 
subject to any long-term side effects. Additionally, following staff remediation and 
education, no additional errors were seen [11]. One way to address this in the ED 
would be to have special teams which are trained specifically in PCAD usage and 
implementation. Studies which have examined the effect of using specially trained 
support staff have demonstrated that there are less adverse events and a greater likeli-
hood of being able to transition to oral opiates (rather than IM) when staff are trained 
appropriately [5, 47]. Thus, it appears that many of these events may be mitigated by 
improving education and regular training among providers and support staff.
There are some additional factors relating to patient perceptions which are 
unique to this modality and may influence its effectiveness in regard to pain control. 
Chumbley and colleagues found that many patients had reservations about using 
PCADs with 22% of patients fearing addiction and 30% fearing overdose [44, 48]. 
The study goes on to explain that lack of education likely played a large role in this 
and a patient’s psychological background and coping abilities were also involved 
in influencing their response to treatment [44]. Intrinsic issues such as these are 
more difficult to control for in an acute setting and are largely related to precon-
ceived notions that patients have prior to presenting to the ED. It is likely that these 
variables could be minimized if providers were to make an effort to first educate 
the patients regarding PCAD use and set reasonable expectations regarding pain 
control prior to the initiation of care.
8. Economics
Although patient safety maintains primacy in the hierarchy of prioritization 
with regard to the implementation of new technology, economic considerations play 
an important role when determining the feasibility of its widespread clinical utility. 
With regard to PCADs there are both hard costs, in terms of the device itself, length 
of stay and medication, as well as soft costs, such as time saved by staff and patient 
satisfaction, which must be considered when analyzing the cost-effectiveness of this 
modality. Although current research clearly demonstrates that there are improve-
ments in patient satisfaction and an objective reduction in pain scores in patients 
receiving patient-controlled analgesia, it is difficult to quantify how these benefits 
translate in terms of savings. As such, clear cost-benefit ratios remain difficult 
to establish. Due to this complexity, a multivariate approach must be used when 
evaluating the benefits that PCADs offer in an acute care setting.
Although device costs vary among distributors it is safe to assume that the cost 
of obtaining the device and subsequent maintenance would be greater than that 
of traditional therapy. A study by Pritchard et al., which evaluated specific costs 
associated with the device including depreciation, electrical testing, calibration/
rebuild costs, and servicing demonstrated that the annual costs of a PCAD was 
approximately $1573 which equates to $4.34 per day [49]. In addition to these initial 
capital expenditures relating to acquiring the device, there is mounting evidence 
that patients receiving patient-controlled analgesia in the ED also require a greater 
quantity of opiates than those receiving IV therapy [9, 33, 42, 44, 46]. These 
increased costs are also compounded by additional administrative challenges which 
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require nursing staff, physicians and pharmacy to coordinate care in a novel manner 
which may be difficult to implement in many EDs.
One factor which clearly favors the use of PCADs in patients experiencing acute 
pain is the ability of this modality to save valuable staff time. This translates to 
increased productivity for both nursing staff and physicians which has the propen-
sity to further increase RVUs and improve overall savings. For example, a recent 
study by Chan et al., demonstrated that PCAD utilization could save an average 
of 10–13 minutes of treatment time within specific post-operative groups [50]. 
Literature on costs related to length of stay, on the other hand, appears equivocal. A 
review of the literature shows that four randomized controlled trials have been done 
which specifically evaluated length of stay in the ED relative to PCAD use. Two 
studies reported an increase in length of stay and two reported a reduction [9, 33, 
41, 43]. None of the studies reached statistical significance, therefore the question 
of whether patient-controlled analgesia reduces length of stay remains unanswered.
The PASTIES study was a large scale randomized trial which evaluated the effec-
tiveness of patient-controlled analgesia in the ED for patients suffering from traumatic 
injuries and non-traumatic abdominal pain [9, 33]. This study evaluated patients 
presenting to the ED who were subsequently admitted to the hospital, thus, provid-
ing important follow-up information on patient outcomes after their initial ED care. 
Subsequent PASTIES studies have since been published which have evaluated the costs 
associated with PCAD use in this cohort. These studies are important to this discussion 
as they are the only studies to date which have specifically evaluated the economic 
feasibility of patient-controlled analgesia in the ED. According to the study there were 
significant reductions in pain, particularly in patients with acute abdominal pain, how-
ever, this came at increased cost. Patients with traumatic injuries incurred an additional 
$21.79–$23.10 per 12 hours; and non-traumatic abdominal pain incurred an additional 
$23.67–$25.09 per 12 hours [49]. Although these costs were significant within the scope 
of this study, they may be negligible as improvements in patient satisfaction may even-
tually translate into improved reimbursement. As such, further studies must be done in 
the future to determine the true financial feasibility of PCAs in this type of setting.
9. Conclusion
Use of patient-controlled analgesia has been demonstrated to be both safe and 
effective for acute pain management in the ED. It offers a means of pain control 
which is more patient-centered and allows for a greater degree of shared decision 
making while simultaneously improving baseline analgesia. Recently, a few small 
scale studies have shown that the use of patient-controlled analgesia in the acute 
care setting may improve objective pain scores and increase both patient and nurse 
satisfaction. However, the economic feasibility for utilization of this modality 
within the scope of the emergency room remains unclear. As always, medica-
tion selection should be guided by clinical presentation and patient response. In 
conclusion, this technology appears to provide a promising alternative to standard 
therapy, however, additional studies must be done before more broad recommenda-
tions can be made regarding widespread implementation.
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